四环医药(00460.HK)加巴喷丁胶囊获内地药品生产批准
四环医药(00460.HK)公布,集团开发的加巴喷丁胶囊已於今年10月15日获得中国国家药品监督管理局颁布的药品生产批准,集团为中国第三家获得生产该产品批准的企业。
集团指,该产品属於《国家基本医疗保险、工伤保险和生育保险药品目录》乙类范围的品种,用於包括治疗疱疹(Postherpetic)感染後神经痛(用於成人疱疹後神经痛的治疗);及癫痫(用於成人和12岁以上儿童伴或不伴继发性全身发作的部分性发作的辅助治疗,也可用於3至12岁儿童的部分性发作的辅助治疗)。(ek/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.